CRUK are seeking an experienced, talented and dedicated synthetic and/or medicinal chemist to join our team at the Drug Discovery Unit led by Professor Caroline Springer at the Cancer Research UK Manchester Institute. The position will be laboratory-based and will require independent design and implementation of complex synthetic routes to yield challenging new chemical entities.
You will bring excellent theoretical and practical expertise in synthetic and/or medicinal
chemistry alongside enthusiasm, creativity and problem solving. A track record in the
synthesis of biologically relevant molecules and the experience to make key intellectual
contributions to projects are also desirable. You will have a BSc in Chemistry or related
subject (or equivalent relevant experience) along with demonstrable, current expertise in
synthetic organic chemistry. PhD or postgraduate level qualification in synthetic organic or medicinal chemistry or related subject (or equivalent relevant experience), would be an advantage. Experience in PROTAC chemistry would be an advantage but is not essential.
The Drug Discovery Unit (DDU) was established in 2009 and has a strong record of candidate drug delivery with successful project collaborations with AstraZeneca, GSK and biotech partners as well as grant funding from CRUK, Wellcome and other charities. The DDU integrates medicinal, computational and synthetic chemistry with advanced biochemical and biophysical assays, in vitro cellular biology and in vivo capability. CRUK's laboratories are located in Alderley Park, Cheshire and are very well equipped. The unit has established facilities to enable state-of-the-art biological and clinical target assessment and validation, small molecule drug design and synthesis and the biological evaluation of the resultant compounds. The DDU builds upon fundamental biology discoveries made within the CRUK Manchester Institute to investigate novel drug discovery targets and to provide new chemical entities for the treatment of unmet clinical needs in cancer patients. The lab's current portfolio encompasses a variety of targets including projects targeting the cancer cell cycle control, tumour stromal regulation, cancer metabolism and suicide gene therapy.
The Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk), an Institute of The University of Manchester (www.manchester.ac.uk), is a world-leading centre for
excellence in cancer research. The Institute is core funded by Cancer Research UK
(www.cancerresearchuk.org), the largest independent cancer research organisation in the world. They are currently situated at The Oglesby Cancer Research Building in South
Manchester and at the internationally-renowned life sciences campus at Alderley Park in
Cheshire England, 15 miles from Manchester, a vibrant and dynamic city surrounded by
beautiful countryside. CRUK are partnered with The Christie NHS Foundation Trust (adjacent to the CRUK MI Paterson Building) in South Manchester (www.christie.nhs.uk), one of the largest cancer Cancer Research UK Manchester Institute is a Research Institute within The University of Manchester and is core funded by Cancer Research UK treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.
To apply for this position please visit our website:
For any informal enquiries about this post, please contact Prof Caroline Springer
(firstname.lastname@example.org) or Dr Dan Niculescu-Duvaz (email@example.com).
Application deadline: 13 May 2021
Application deadline: 13 May 2021
The EACR is grateful for the continued support of its Industry Partners: